Breakthrough Targeted Therapeutic Approaches to Squamous Cell Carcinoma of the Head and Neck

References

• Kamangar F , DoresGM, AndersonWF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24, 2137–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Tettamanti L , CaprioglioA, TeccoSet al. Oral squamous cell carcinoma in the paediatric patient: a literature review. Eur. J. Paediatr. Dent.13, 35–40 (2012).
   PubMed Web of Science ®Google Scholar
• Grégoire V , LefebvreJ-L, LicitraL, FelipE. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21, 184–186 (2010).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guideline in oncology: head and neck cancer. V.2.2013. www.nccn.org
   Google Scholar
• Vermorken JB , MesiaR, RiveraFet al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359, 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Bonner JA , HarariPM, GiraltJet al. Radiotherapy plus cetuximab for locoregionaly advanced head and neck cancer: 5-year survival data from a Phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol.11, 21–28 (2010).
   PubMed Web of Science ®Google Scholar
• Bonner JA , HarariPM, GiraltJet al. Radiotheraphy plus cetuximab for squamous cell carcinoma of the head and neck N. Engl. J. Med. 354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Kalyankrishna S , GrandisJR. Epidermal growth factor biology in head and neck cancer. J. Clin. Oncol.24, 2666–2672 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitz S , AngKK, VermorkenJet al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat. Rev.40, 390–404 (2014).
   PubMed Web of Science ®Google Scholar
• Yarden Y , PinesG. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer12, 553–563 (2012).
   PubMed Web of Science ®Google Scholar
• Harbeck N , SolcaF, GaulerTC. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future Oncol.10, 21–40 (2014).
   PubMed Web of Science ®Google Scholar
• Ang KK , ZhangQ, RosenthalDIet al. A randomized Phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas (HNC). J. Clin. Oncol.29(15 Suppl.), 5500 (2011).
   Web of Science ®Google Scholar
• Herbst RS , ArquetteM, ShinDMet al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol.23, 5578–5587 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken JB , TrigoJ, HittRet al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol.25, 2171–2177 (2007).
   PubMed Web of Science ®Google Scholar
• Giralt J , FortinA, MesiaRet al. A Phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J. Clin. Oncol.30(15), 2000 (2012).
   Web of Science ®Google Scholar
• Babu KG , ViswanathL, ReddyBKet al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J. Clin. Oncol.28(15), 5530 (2010).
   Google Scholar
• Gan HK , BurgeME, SolomonBJet al. A Phase I and biodistribution study of ABT-806i, an indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J. Clin. Oncol.31(15 Suppl.), 2520 (2013).
   Web of Science ®Google Scholar
• Stewart JS , CohenEE, LicitraLet al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.27, 1864–2009 (1871).
   Google Scholar
• Swanton C . Intratumour heterogeneity: evolution through space and time. Cancer Res.72, 4875–4882 (2012).
   PubMed Web of Science ®Google Scholar
• McCabe C , BergmannL, BosanquetNet al.; Biotherapy Development Association. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann. Oncol.20, 403–412 (2009).
   PubMed Web of Science ®Google Scholar
• Machiels JP , SchmitzS. The importance of window opportunity studies. Ann. Oncol.23, 42–43 (2012).
   Web of Science ®Google Scholar
• Schmitz S , HamoirM, ReychlerHet al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann. Oncol.24, 2261–2266 (2013).
   PubMed Web of Science ®Google Scholar
• Mangano A , DionigiG. The need for standardized technique in intraoperative monitoring of the external branch of the superior laryngeal nerve during thyroidectomy. Surgery149, 854–855 (2011).
   PubMed Web of Science ®Google Scholar
• Dionigi G , Van SlyckeS, BoniL, RauseiS, ManganoA. Limits of neuromonitoring in thyroid surgery. Ann. Surg.258, 1–2 (2013).
   PubMed Web of Science ®Google Scholar
• Dionigi G , ChiangFY, DralleHet al. Safety of neural monitoring in thyroid surgery. Int. J. Surg.11(Suppl. 1), S120–S126. (2013).
   PubMedGoogle Scholar
• Dionigi G , DonatiniG, BoniLet al. Continuous monitoring of the recurrent laryngeal nerve in thyroid surgery: a critical appraisal. Int. J. Surg.11(Suppl. 1), S44–S46 (2013).
   PubMedGoogle Scholar